Navigation Links
Denali Concrete Management Inc. Announces the Commencement of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study
Date:12/21/2011

CARSON CITY, Nev., Dec. 21, 2011 /PRNewswire/ -- Denali Concrete Management Inc. (OTCBB: DCMG) announced today that it has commenced patient enrollment for a phase 3 clinical study of the safety and efficacy of CF101, daily administered orally, in patients with moderate-to-severe Dry Eye Syndrome. This multi-center clinical trial is conducted in the United States, Europe and Israel. The randomized, double-masked clinical trial will include 231 patients who will be randomized to receive 2 doses of CF101 and Placebo, for a period of 24 weeks.  The primary efficacy endpoint will be complete clearing of corneal staining.

The population suffering from Dry Eye Syndrome is estimated at 49 million people in the seven major markets and is characterized by eye irritation symptoms, blurred and fluctuating vision, tear film instability, increased tear osmolarity and ocular surface epithelial disease. People with Dry Eye Syndrome experience constant ocular discomfort and a decrease in visual function; in severe cases, Dry Eye Syndrome may result in deterioration of vision.

Dr. Pnina Fishman, the Company's interim CEO stated, "We are very pleased with the initiation of enrollment to the Dry Eye Syndrome phase 3 study. The positive data from the previous phase 2 study as well as the excellent safety profile of CF101 indicates the potential of this innovative oral drug for the treatment of Dry Eye Syndrome."

In addition, the Company announces today that by action of the Board of Directors and the shareholders, it has changed its name to OphthaliX Inc.

About CF101

CF101, an A3 adenosine receptor agonist, is a novel, first in class, small molecule, orally bioavailable drug with a proven efficacy in Phase 2 clinical studies and an excellent safety profile. CF101 is currently developed for ophthalmic indications including Dry Eye Syndrome (Phase 3), Glaucoma (Phase 2) and Uveitis. CF101 is also developed for the treatment of autoimmune inflammatory diseases including Rheumatoid Arthritis (Phase 2b) and Psoriasis (Phase 2/3).

About OphthaliX Inc (formerly Denali Concrete Management Inc).

OphthaliX Inc. (OTCBB: DCMG) is an advanced clinical-stage biopharmaceutical company focused on developing therapeutic products for the treatment of ophthalmic disorders. Denali's product candidate, CF101, is being developed to treat three ophthalmic indications: dry eye syndrome; glaucoma and uveitis.

This release contains forward-looking statements regarding Denali Concrete Management, Inc.'s future plans and expected performance based on assumptions the Company believes to be reasonable.  A number of risks and uncertainties could cause actual results to differ materially from these statements, including, without limitation, the success rate of business development efforts and the timeliness of development activities, and other risk factors described from time to time in the Company's reports filed with the SEC.  In addition, the Company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond the Company's control. Denali Concrete Management, Inc. undertakes no obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise. 


'/>"/>
SOURCE Denali Concrete Management Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Denali Concrete Management Inc. Announces its Acquisition of CF101 for Ophthalmic Indications and the Completion of Above $6 Million Private Placement at $1.144 Per Share
2. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
3. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
4. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
5. Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
6. U.S. Preventive Medicine Acquires Specialty Disease Management
7. Cellectar Expands Clinical Management Team
8. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
9. New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
10. Lilly Receives NCQA Design Certification for Depression Care Management Program
11. Micromet Announces Changes in Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017  Additive Orthopaedics, LLC., an early ... has kicked off a multi-centered clinical study to ... segments. According to Brian McLaughlin ... lattice structures have already shown tremendous post-operative success ... allograft wedges from which we have seen evidence ...
(Date:3/23/2017)... 23, 2017 Newborns are highly vulnerable ... vaccines because their young immune systems typically mount ... Hospital report achieving strong vaccine responses in newborn ... before human trials — by adding compounds known ... two simultaneous papers, they also describe improved adjuvant ...
(Date:3/23/2017)...  A new genetic test has been discovered ... who carry HLA-B*15:02 and who are ... deadly side effect of certain medications used to ... HLA-B*15:02 is strongly associated with life-threatening severe ... toxic epidermal necrolysis in patients treated with carbamazepine ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... ... 150+ Hospital and Health System Executive Speakers including: , , Chief ... the United States of America: George W. Bush , Boxing Legend, Successful Entrepreneur ... Leonard , JD, Chairperson, McGuireWoods LLP: Amber McGraw Walsh , Senior ...
(Date:3/23/2017)... Grants Pass, OR (PRWEB) , ... March 23, 2017 , ... ... Power of Water, Global Climate Change and Your Health on VoiceAmerica, recently talked on ... 22nd, but she also used the occasion to remind listeners of an important distinction. ...
(Date:3/23/2017)... ... March 23, 2017 , ... Natural ... all aspects of people’s health and nutrition, announced its product Leyzene is now ... Natural Subsistence develops nutritional supplements that help people improve all aspects of their ...
(Date:3/23/2017)... ... ... Inflow IQ & Inflownomics of Raleigh, NC introduce a powerful information access network. ... experts in dangerous situations the Inflow IQ team can help people. Get ready ... & refreshing knowledge systems that enhance life. , Authentically enjoy 500 ...
(Date:3/23/2017)... ... , ... The American Board of Quality Assurance and Utilization Review Physicians (ABQAURP) ... Health Care Quality and Management and Patient Safety. , It is with appreciation and ... also to the Health Care Quality and Patient Safety movements. Diplomates and Members lead ...
Breaking Medicine News(10 mins):